Canadian Authorities Say Janssen Did Not Choke Competition For Infliximab – But Will Keep Spotlight On Originator Abuse Of Power

 
• By Dean Rudge
  
CanadianFlags
Sufficient evidence was not found showing J&J foreclosed biosimilar competition to Remicade (infliximab), Canada's Competition Bureau said. • Source: Shutterstock

More from Biosimilars

More from Products